Anergia-anhedonia by Lithium-induced Phosphorus Diabetes

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Lithium (Li+) is prescribed to 1‰ of the French population (\ 60,000 patients). More than half of patients describe subjective symptoms linked to Li+ (SSL) similar to those of chronic fatigue syndrome: muscle weakness, fatigability, cognitive disorders, emotional blunting. SSL are the 2nd cause of stopping Li+ (28%), just behind kidney problems (30%). In animals, the administration of lithium (Li+) increases the urinary excretion of phosphate (Pi) by 6, inducing phosphate diabetes (DPi). However, idiopathic forms of DPi explain up to 10-15% of chronic fatigue syndromes and these disappear when supplementing with Pi (± vitamin D). In humans, the introduction of Li+ leads to a reduction in serum phosphate but we have not found any publication on the possible induction of DPi or on a possible link between DPi and SSL. However, the dosages necessary to detect a DPi are carried out during the annual follow-up assessment of patients on Li+. All you have to do is calculate the standardized maximum reabsorption rate of Pi (TmPi) to make the diagnosis! Finally, if the patients presenting with DPi turn out to be the same as those who complain of SSL, we can imagine that correcting the first by simple supplementation with Pi (± vitamin D) could provide relief.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Major subject (≥ 18 years old)

• Man or woman

• Subject balanced on Li+ (\> 6 months, regardless of the underlying pathology).

• Outpatient monitoring by one of the members of CEDRA (Alsace expert center for resistant depression).

• Subject not opposing, after information, the reuse of their data for the purposes of this research

Locations
Other Locations
France
CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France
RECRUITING
Strasbourg
Contact Information
Primary
Jack FOUCHER, MD, PhD
jack.foucher@chru-strasbourg.fr
33 3 88 11 69 21
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2024-04-24
Participants
Target number of participants: 60
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov